Psychiatrists saw more patients and were responsible for a greater number of prescriptions in 1998.
Psychiatrists saw more patients and were responsible for a greater number of prescriptions in 1998, according to a recent report released by Newtown, PA-based Scott-Levin.
For the 12 months ending October 1998, psychiatrists received more than 58 million visits - an increase of 4% over the year before.
As a result of those consultations, they wrote 93.1 million retail prescriptions, or 1,815 prescriptions per doctor. That's 5% more prescriptions than the number psychiatrists wrote the year before. In total, psychiatrists were responsible for $5.6 billion in retail prescription sales.
"The main fact could be that psychiatrists have had a lot more attention lately from specialty sales forces. They are receiving a lot more details, mainly due to the companies' strategies," said Andrew Diefes, a marketing research analyst for Scott-Levin, when asked why psychiatrists were writing a greater volume of prescriptions.
According to Scott-Levin, the top products prescribed by psychiatrists were the same drugs that were most detailed. Prozac accounted for 8.1% of prescriptions, Zoloft received 5.4% of prescriptions and Paxil accounted for 5% of prescriptions.
By therapeutic class, the top five classes prescribed by psychiatrists were: specific neurotransmitter modulators, such as selective serotonin receptor inhibitors and selective NR inhibitors, (24.5%); seizure disorder therapies, (10.4%); antipsychotics, (9.5%); benzodiazepines, (9.3%); and similar antidepressants, (7.5%).
Sales reps made 2.6 million details to psychiatrists for the year ended October 1998, making psychiatrists the fifth most detailed group of doctors. PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.